Skip to main content
//empty //empty
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

Omeros Corp said on Monday its experimental treatment helped six patients, with acute respiratory distress syndrome caused by COVID-19, recover and get discharged from the hospital, sending the drug developer’s shares up 60 per cent.

The company said it was in talks with the U.S. government for potential funding to speed up large-scale manufacturing for broader availability of the treatment, narsoplimab.

All six patients had underlying conditions and needed mechanical ventilation before treatment, Omeros said.

Story continues below advertisement

Acute respiratory distress syndrome, or ARDS, causes fluid to collect in the lungs, depriving organs of oxygen. COVID-19 patients with ARDS often require intensive care.

The small study was done in Italy’s Bergamo, the initial epicentre of COVID-19 in Europe, under a compassionate use program following requests from doctors at the Papa Giovanni XXIII hospital.

Narsoplimab is a human monoclonal antibody that recognizes and locks onto a virus, preventing the infection from spreading. The company said it targets damage to endothelial cells, a general marker of both the disease and recovery.

The therapy has already been studied in a pivotal trial for a stem cell transplant-related complication and in late-stage studies for two kidney conditions. Narsoplimab was also granted U.S. FDA’s breakthrough tag for these indications, but the agency has not yet approved the drug for any use.

The U.S. government, under its “Operation Warp Speed” initiative aimed at accelerating access to vaccines and treatments to fight COVID-19, has so far agreed to invest more than $7-billion in vaccines and has funded more than 30 projects, including those for diagnostics and treatments.

Omeros did not provide further details of its talks with the U.S. government. It did not immediately respond to a Reuters request for additional comments.

The company’s shares rose as much as 80 per cent to a two-year high of $25.46, before trading at $22.18.

Story continues below advertisement

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Follow related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies